A growing number of lawsuits allege that Ozempic and related weight management drugs cause severe gastrointestinal injuries. Plaintiffs in these cases claim that Novo Nordisk and Eli Lilly and Co., the makers of semaglutide medications for diabetes and weight loss, failed to adequately warn patients and health care providers about the potential risks associated with the medications.